MedeliX
Start asking

Adenosine

Adenosin Baxter, Adenosin Hikma, Adenosin Macure · ATC code C01EB10

Also known as: Adenosin, Adenozin, Adenosina, Adénosine · Brand names: Adenoscan, Adenosin Altamedics, Adenosin Baxter, Adenosin Hikma, Adenosin Life Medical, Adenosin Macure, Adenosin Rotop, Adrekar, Adenosin-L.m., Adenotek, Adesan, Adozin

Key facts
Active substance
Adenosine
ATC code
C01EB10
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-11-06

Key facts

Adenosine is an endogenous nucleoside that slows conduction through the A-V node. Per the US label the injection is used as a rapid intravenous bolus to convert paroxysmal supraventricular tachycardia (PSVT).

What it is used for

  • Conversion to sinus rhythm of PSVT, including PSVT with accessory pathways (Wolff-Parkinson-White syndrome); try vagal manoeuvres first when advisable
  • Not effective for atrial flutter, atrial fibrillation or ventricular tachycardia

Dosing

  • Rapid peripheral intravenous bolus over 1 to 2 seconds, close to the patient, followed by a rapid saline flush
  • Adults: 6 mg; if no conversion within 1 to 2 minutes, 12 mg, which may be repeated a second time
  • Children under 50 kg: 0.05 to 0.1 mg/kg, increasing by 0.05 to 0.1 mg/kg until conversion or a maximum single dose of 0.3 mg/kg
  • Children 50 kg or more: adult dose; doses greater than 12 mg are not recommended

Contraindications

  • Second- or third-degree A-V block, unless a functioning pacemaker is present
  • Sinus node disease (sick sinus syndrome, symptomatic bradycardia), unless a functioning pacemaker is present
  • Known hypersensitivity to adenosine

Important warnings

  • Transient heart block and asystole, occasionally fatal; no further doses after high-level block; resuscitation equipment must be available
  • Ventricular fibrillation reported rarely, mostly with digoxin or digoxin plus verapamil
  • Transient new rhythms at conversion (seen in 55% of patients)
  • Avoid in bronchoconstriction or bronchospasm (e.g. asthma); caution in obstructive lung disease

Side effects

  • Facial flushing (18%), dyspnoea (12%), chest pressure (7%)
  • Nausea (3%), headache (2%), lightheadedness (2%)
  • Postmarketing: prolonged asystole, ventricular tachycardia or fibrillation, Torsade de Pointes, bronchospasm, seizures

Interactions

  • Caffeine and theophylline antagonise adenosine: larger doses may be needed or it may not work
  • Dipyridamole potentiates adenosine: smaller doses may be effective
  • Carbamazepine may increase the degree of heart block
  • Digoxin, verapamil: rare ventricular fibrillation; use with caution

Pregnancy and breastfeeding

  • No studies in pregnant women; use during pregnancy only if clearly needed

Summary of the official product information, written with AI on 2026-11-14. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Germany

  • AdenoscanSanofi-Aventis Deutschland Gmbh · 1 register entry
  • Adenosin AltamedicsAltamedics Gmbh · 1 register entry
  • Adenosin BaxterBaxter Holding B.V. · 1 register entry
  • Adenosin HikmaHikma Farmacêutica (Portugal), S.A. · 1 register entry
  • Adenosin Life MedicalEvolan Pharma Ab · 2 register entries
  • Adenosin MacureMacure Healthcare Limited · 1 register entry
  • Adenosin RotopRotop Pharmaka Gmbh · 1 register entry
  • AdrekarSanofi-Aventis Deutschland Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-11-06

Austria

  • Adenosin BaxterBaxter Holding B.V. · 1 register entry
  • Adenosin HikmaHikma Farmacêutica (Portugal), S.A. · 1 register entry
  • Adenosin MacureMacure Healthcare Limited · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-11-06

Turkey

  • Adenosin-L.m.ABFEN FARMA SAN. VE TİC.LTD. ŞTİ. · 3 register entries
  • AdenotekFARMA-TEK İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
  • AdesanTURKTIPSAN SAĞLIK TURİZM EĞİTİM VE TİC. A.Ş. · 2 register entries
  • AdozinVEM İLAÇ SAN. VE TİC. A.Ş. · 4 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-11-06

Brand names in 21 more European countries
Belgium
Adenocor, Adenosine Fresenius Kabi, Adenosine Hikma
Cyprus
Caden
Czechia
Adenocor
Denmark
Adenocor, Adenosin Fresenius Kabi, Adenosin Life Medical, Adenosin Macure
Estonia
Adenosin Life Medical
Finland
Adenosin Life Medical, Adenosin Macure
France
Adenoscan, Adenosine Hikma, Adenosine Medisol, Krenosin
Greece
Adenorythm
Hungary
Adenocor
Ireland
Adenocor, Adenosine
Italy
Adenoscan, Adenosina Hikma, Adenosina Kabi, Krenosin
Lithuania
Adenosine Life Medical
Luxembourg
Adenocor
Malta
Adenorythm
Netherlands
Adenocor, Adenosine Fresenius Kabi, Adenosine Hikma
Norway
Adenosin Life Medical, Adenosin Macure
Poland
Adenocor
Portugal
Adenoscan, Adenosina Baxter, Adenosina Hikma, Adenosina Kabi, Caden
Slovakia
Adenocor
Spain
Adenocor, Adenoscan, Adenosina Hikma, Adenosina Kabi
Sweden
Adenosin Life Medical, Adenosin Macure

EMA – Article 57 product data (EU/EEA), 2026-11-06

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Adenosine (Sagent Pharmaceuticals) – Prescribing Information, 2026-07-27. DailyMed (NLM), 2026-11-06. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=546642f2-662f-46cf-9d82-5bb3bdcc7677
  2. EMA – Article 57 product data (EU/EEA), 2026-11-06. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-11-06. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-11-06. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-11-06 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.